亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Effects of complete revascularization according to age in patients with ST-segment elevation myocardial infarction and multivessel disease (COMPLETE-AGE)

医学 传统PCI 四分位间距 心肌梗塞 血运重建 罪魁祸首 经皮冠状动脉介入治疗 内科学 心脏病学 血管成形术 外科
作者
Kevin R. Bainey,David Wood,Matthias Bossard,Gianluca Campo,Warren J. Cantor,Shahar Lavi,Mina Madan,Roxana Mehran,Natalia Pinilla‐Echeverri,Sunil V. Rao,Jaydeep Sarma,Tej Sheth,Goran Stanković,Philippe Gabríel Steg,Robert F. Storey,Jean‐François Tanguay,James L. Velianou,Robert C. Welsh,Thenmozhi Mani,John A. Cairns
出处
期刊:American Heart Journal [Elsevier BV]
卷期号:267: 70-80 被引量:11
标识
DOI:10.1016/j.ahj.2023.10.004
摘要

In ST-segment elevation myocardial infarction (STEMI), complete revascularization with percutaneous coronary intervention (PCI) reduces major cardiovascular events compared with culprit-lesion-only PCI. Whether age influences these results remains unknown. COMPLETE was a multinational, randomized trial evaluating a strategy of staged complete revascularization, consisting of angiography-guided PCI of all suitable nonculprit lesions, versus a strategy of culprit-lesion-only PCI. In this prespecified subgroup analysis, treatment effect according to age (≥65 years vs <65 years) was determined for the first coprimary outcome of cardiovascular (CV) death or new myocardial infarction (MI) and the second coprimary outcome of CV death, new MI, or ischemia-driven revascularization (IDR). Median follow-up was 35.8 months (interquartile range [IQR]: 27.6-44.3 months). Of 4,041 patients randomized in COMPLETE, 1,613 were aged ≥ 65 years (39.9%). Higher event rates were observed for both coprimary outcomes in patients aged ≥ 65 years comparted with those aged < 65 years (11.2% vs 7.9%, HR 1.49, 95% CI 1.22-1.83; 14.4% vs 11.8%, HR 1.28, 95% CI 1.07-1.52, respectively). Complete revascularization reduced the first coprimary outcome in patients ≥ 65 years (9.7% vs 12.5%, HR 0.77; 95% CI, 0.58-1.04) and < 65 years (6.7% vs 9.1%, HR 0.72; 95% CI, 0.54-0.96)(interaction P = .74). The second coprimary outcome was reduced in those ≥ 65 years (HR 0.56, 95% CI, 0.43-0.74) and < 65 years (HR 0.48, 95% CI, 0.37-0.61 (interaction P = .37). A sensitivity analysis was performed with consistent results demonstrated using a 75-year threshold (albeit attenuated). In patients with STEMI and multivessel CAD, complete revascularization compared with culprit-lesion-only PCI reduced major cardiovascular events regardless of patient age and could be considered as a revascularization strategy in older adults.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
生动盼兰完成签到,获得积分10
1秒前
corleeang完成签到 ,获得积分10
9秒前
闪闪的水彤完成签到,获得积分10
51秒前
冷酷的冰枫完成签到,获得积分10
1分钟前
taku完成签到 ,获得积分10
1分钟前
霄泽完成签到,获得积分10
1分钟前
伶俐的一斩完成签到,获得积分10
2分钟前
2分钟前
2分钟前
ccbk2062发布了新的文献求助10
2分钟前
研究牛牛发布了新的文献求助10
2分钟前
molihuakai应助lifesci_ming采纳,获得10
2分钟前
2分钟前
2分钟前
lifesci_ming发布了新的文献求助10
2分钟前
隐形大地完成签到,获得积分10
2分钟前
琴风萤完成签到,获得积分10
2分钟前
ccbk2062完成签到,获得积分10
3分钟前
高大山兰完成签到,获得积分10
3分钟前
酷波er应助pete采纳,获得10
3分钟前
L_完成签到 ,获得积分10
3分钟前
icanccwhite发布了新的文献求助20
3分钟前
3分钟前
FashionBoy应助2025211022采纳,获得10
4分钟前
平淡夏青完成签到,获得积分10
4分钟前
icanccwhite完成签到,获得积分10
4分钟前
4分钟前
4分钟前
pete发布了新的文献求助10
4分钟前
拂晓发布了新的文献求助20
4分钟前
顺心的伯云完成签到,获得积分10
4分钟前
小叙完成签到 ,获得积分10
4分钟前
拂晓完成签到,获得积分10
4分钟前
JEREMIAH完成签到,获得积分10
5分钟前
桐桐应助OK采纳,获得25
6分钟前
无极微光应助zx采纳,获得20
7分钟前
霸气侧漏发布了新的文献求助10
8分钟前
8分钟前
OK发布了新的文献求助25
8分钟前
0x10c完成签到,获得积分20
8分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Prompt Engineering for Clinicians: Harnessing AI in Everyday Medical Practice 600
REAL-WORLD EFFICACY AND GENOMIC LANDSCAPE OF POLATUZUMA VEDOTIN-BASED FIRST-LINE THERAPY IN DIFFUSE LARGE B-CELL LYMPHOMA: A FOCUS ON TP53 MUTATIONS AND TREATMENT RESPONSE 500
Handbook of Luminescence Dating 500
Safety Pharmacology 500
《KNN基无铅压电陶瓷电学性能优化与物理机理研究》 500
Treatment of refractory idiopathic overactive bladder with incobotulinumtoxinA and vibe delivery system (XAVIER): pilot study 400
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 计算机科学 化学工程 生物化学 物理 内科学 复合材料 催化作用 光电子学 物理化学 电极 细胞生物学 基因 遗传学
热门帖子
关注 科研通微信公众号,转发送积分 6948148
求助须知:如何正确求助?哪些是违规求助? 8632894
关于积分的说明 18307792
捐赠科研通 6386943
什么是DOI,文献DOI怎么找? 3080738
关于科研通互助平台的介绍 2123857
邀请新用户注册赠送积分活动 2057637